Advancements in treating central nervous system lymphoma (CNSL) show promise as a recent study highlights the effectiveness of a tailored autologous stem cell transplantation (ASCT) approach within the Asian population.
Innovative Conditioning Regimen Tested
Researchers conducted a phase II trial, enrolling 17 patients initially before expanding the study to include a total of 44 participants. The study assessed the outcomes of a thiotepa/busulfan/cyclophosphamide (TBC) conditioning regimen followed by ASCT. Patients received either an 8-day or 9-day TBC regimen, adjusted based on their age and overall health status.
Promising Response Rates Observed
Results revealed that 75% of patients achieved an objective response post-ASCT, with 32 attaining complete response and one showing partial response. The three-year progression-free survival rates were comparable between the 8-day and 9-day groups, standing at 46.5% and 52.6% respectively. Similarly, overall survival rates over three years were 60.5% for the shorter regimen and 73.7% for the longer one, indicating no significant difference.
- The 8-day regimen may reduce non-relapse mortality, showing a lower one-year incidence compared to the 9-day regimen.
- Primary CNSL constituted over half of the study participants, underscoring the regimen’s applicability to initial diagnoses.
The study underscores the efficacy of the TBC/ASCT protocol in treating CNSL among Asian patients. Notably, the conventional 9-day busulfan dose appears linked to higher toxicity, suggesting that a modified shorter regimen could enhance patient outcomes by minimizing adverse effects.
Further research is essential to optimize thiotepa-based conditioning protocols. Understanding the balance between efficacy and safety will be crucial in refining treatments for CNSL, potentially leading to standardized guidelines that cater to diverse patient populations.
Healthcare providers should consider the benefits of the 8-day TBC regimen, especially for patients who may be more susceptible to treatment-related toxicity. Personalized treatment plans that account for individual patient profiles can improve survival rates and quality of life for those battling CNSL.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
